57544-18-0

Basic information

• Product Name: 6-Bromo-2-(4-chlorophenyl)-3-nitro-2H-1-benzopyran
• Synonyms: 6-Bromo-2-(4-chlorophenyl)-3-nitro-2H-1-benzopyran
• CAS NO: 57544-18-0
• Molecular Formula: C₁₅H₉BrClNO₃
• Molecular Weight: 366.59
• Mol File: 57544-18-0.mol

Chemical Properties

• Boiling Point: 484.7°C at 760 mmHg
• Flash Point: 246.9°C
• Appearance: /
• Density: 1.69g/cm³
• Vapor Pressure: 4.46E-09mmHg at 25°C
• Refractive Index: 1.696
• CAS DataBase Reference: 6-Bromo-2-(4-chlorophenyl)-3-nitro-2H-1-benzopyran(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-2-(4-chlorophenyl)-3-nitro-2H-1-benzopyran(57544-18-0)
• EPA Substance Registry System: 6-Bromo-2-(4-chlorophenyl)-3-nitro-2H-1-benzopyran(57544-18-0)

Safety Data

• Hazardous Substances Data: 57544-18-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C15H9BrClNO3/c16-11-3-6-14-10(7-11)8-13(18(19)20)15(21-14)9-1-4-12(17)5-2-9/h1-8,15H

Upstream product

• 706-07-0 1-chloro-4-(2-nitrovinyl)benzene 
• 1761-61-1 5-bromosalicyclaldehyde 

Relevant articles and documents

Molecular diversity of the domino annulation reaction of 2-aryl-3-nitrochromenes with pivaloylacetonitriles

In the presence of triethylamine, the domino annulation reaction of two molecules of pivaloylacetonitrile with one molecule of 2-aryl-3-nitrochromene in tetrahydrofuran resulted in the unprecedented imino-substituted dihydrofuro[2,3-c]chromene derivatives in high yields. More importantly, the above domino reaction in refluxing methanol or ethanol afforded alkoxy-substituted chromeno[3,4-b]pyridines in satisfactory yields. However, a similar reaction of benzoylacetonitrile with 2-aryl-3-nitrochromenes in basic medium gave the expected furo[2,3-c]chromene derivatives in moderate yields.

NEW PI3K/AKT/MTOR INHIBITORS AND PHARMACEUTICAL USES THEREOF

The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant re

New PI3K/AKT/mTOR inhibitors and pharmaceutical uses thereof

The invention relates to new PI3K/AKT/mTOR inhibitors of formula (I) and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.

A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells

Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chemical syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. (Figure Presented).